Last updated: September 9, 2026
Hemin for injection is a small, orphan acute-care market led in the United States by Panhematin, marketed by Recordati Rare Diseases. Demand is driven by acute hepatic porphyria, particularly acute intermittent porphyria, rather than by a large chronic-treatment population. The product has limited direct competition, no meaningful remaining regulatory exclusivity, and a commercial profile shaped more by supply reliability, specialist diagnosis, hospital access, and rare-disease pricing than by patent protection.
Recordati does not publicly disclose Panhematin revenue separately. Its contribution is included within broader specialty and rare-disease reporting, preventing a reliable standalone revenue trend from public company filings. [1]
What is hemin for injection and who markets it?
Hemin for injection is an intravenous heme replacement therapy used to treat recurrent attacks of acute intermittent porphyria linked to elevated hepatic heme precursor production. In the United States, the principal branded product is Panhematin, supplied as a 313-mg lyophilized vial for reconstitution. [2]
| Item |
Detail |
| Active ingredient |
Hemin |
| U.S. brand |
Panhematin |
| U.S. marketing company |
Recordati Rare Diseases |
| Dosage form |
Lyophilized powder for intravenous infusion |
| Strength |
313 mg per vial |
| Primary disease |
Acute intermittent porphyria and related acute hepatic porphyrias |
| Typical use |
Acute attacks; selected recurrent cases under specialist management |
| U.S. regulatory pathway |
Legacy NDA approval |
| FDA approval history |
Original approval predates modern orphan-drug commercialization |
| Principal commercial channel |
Hospitals, specialty pharmacies, porphyria centers, and emergency-care networks |
Recordati obtained U.S. rights to Panhematin from Lundbeck in a transaction involving Lundbeck’s U.S. rare-disease portfolio. The product now sits within Recordati’s rare-disease business alongside other specialty medicines. [1]
How large is the hemin injection market?
The U.S. market is small in patient volume but high in revenue per treated patient. Acute hepatic porphyria is rare, diagnosis is often delayed, and treatment is concentrated among specialist centers. A single acute attack can require several daily infusions, while patients with recurrent attacks may receive repeated courses or preventive therapy.
The market has five structural characteristics:
- Demand is medically concentrated. Most utilization comes from a limited number of porphyria specialists, hospitals, and emergency departments.
- Treatment is episodic. Volume depends on attack frequency, diagnosis rates, hospitalization patterns, and access to specialist care.
- The product is difficult to substitute in acute care. Intravenous hemin is a direct replacement therapy, while glucose and other supportive measures do not provide the same pharmacologic effect.
- Supply continuity is commercially important. Hospitals may hold or source emergency inventory because a delay in treatment can extend an attack and increase hospital resource use.
- Pricing is less sensitive to ordinary generic competition than in high-volume therapeutic categories.
Public sources do not provide a verified global sales figure for hemin injection or a separate Panhematin revenue line. Market-research estimates should be treated cautiously because they often combine hemin, heme arginate, diagnostic services, and investigational porphyria therapies.
What is the financial trajectory of Panhematin and hemin for injection?
The public financial trajectory is best characterized as stable specialty-product revenue with limited volume growth and potential price-driven expansion. Recordati reports consolidated and portfolio-level sales rather than product-level Panhematin sales. [1]
| Financial driver |
Expected effect on Panhematin economics |
| Increased diagnosis of acute hepatic porphyria |
Supports unit growth |
| Greater specialist awareness |
Supports earlier treatment and repeat use |
| Recurrent attacks |
Increases annual revenue per identified patient |
| Hospital stocking |
Supports channel stability |
| Price increases |
Can raise revenue without significant volume growth |
| Generic or alternative hemin entry |
Could reduce price and market share |
| New disease-modifying therapies |
Could reduce recurrent acute attacks |
| Manufacturing interruption |
Can create short-term revenue volatility and customer switching |
| Limited patient population |
Restricts long-term volume expansion |
Recordati’s broader financial performance has benefited from rare-disease and specialty products, but Panhematin is not large enough to be identified publicly as a separate corporate growth engine. Its financial value is more consistent with a niche cash-generating asset than with a major platform product.
The commercial asset has several favorable characteristics: established FDA history, a recognized clinical role, specialist prescribing concentration, limited direct competition, and high switching friction during acute attacks. Its limitations are the small addressable population, lack of meaningful patent exclusivity, and exposure to new therapies that could reduce attack frequency.
When does hemin for injection lose exclusivity?
Panhematin’s original FDA approval occurred in the early 1980s. Any seven-year orphan-drug exclusivity associated with the original approval expired decades ago. The product also predates the modern patent-centered lifecycle model used for newer biologics and small-molecule medicines. [2,3]
| Exclusivity category |
Panhematin status |
| Orphan-drug exclusivity |
Expired |
| New chemical entity exclusivity |
Not applicable to the legacy product |
| Pediatric exclusivity |
No material current protection identified |
| Patent-based exclusivity |
No commercially significant active protection identified in standard FDA product listings |
| Regulatory exclusivity remaining |
None expected from the original approval |
| Data exclusivity |
Not a current commercial barrier |
Hemin is a naturally occurring heme preparation rather than a new molecular entity with a conventional composition-of-matter patent estate. The commercial defense has therefore relied on manufacturing know-how, regulatory history, distribution, physician familiarity, and market size rather than on long-lived patent claims.
What is the Orange Book status of Panhematin?
Panhematin is listed in FDA drug-information materials as an approved prescription product. The product’s commercial protection does not depend on a current Orange Book patent barrier. FDA Orange Book records should be checked for the latest application and product-specific listing before a Paragraph IV or abbreviated new drug application strategy is finalized. [3]
The key implications are:
- There is no apparent active patent wall comparable to that of a recently approved specialty drug.
- An ANDA sponsor would need to address pharmaceutical equivalence, sterility, manufacturing controls, labeling, and clinical-risk considerations.
- The absence of patent protection does not guarantee rapid generic entry.
- For a sterile injectable used in rare disease, manufacturing validation and commercial scale can be more important than patent clearance.
Are there Paragraph IV challenges to hemin for injection?
No major publicly documented, commercially consequential Paragraph IV campaign against Panhematin is established in the core public record through the available product and litigation information. The absence of a visible challenge is consistent with the market’s small size and the technical burden of sterile injectable development.
A potential ANDA sponsor would face several barriers:
Sterile injectable manufacturing
Hemin products require controlled sterile manufacturing, validated reconstitution and infusion procedures, stability data, container-closure testing, and management of particulate and aggregation risks. These requirements raise development costs relative to ordinary oral generic products.
Limited market scale
The number of treated patients is small. A generic entrant would need sufficient share and pricing discipline to recover development, regulatory, manufacturing, and pharmacovigilance costs.
Clinical substitution risk
Hospitals may prefer an established supplier during an acute porphyria attack, especially when the alternative has limited market history. A generic would need to demonstrate reliable supply and gain acceptance from specialist centers.
Product complexity
Although hemin is not a biologic in the same sense as a monoclonal antibody, injectable hemin is more operationally complex than a conventional tablet. Differences in formulation, excipients, reconstitution, infusion compatibility, and storage can affect hospital adoption.
What formulation patents protect hemin for injection?
No material formulation-patent estate is publicly associated with Panhematin as a current market barrier. The main technical protection is likely to reside in manufacturing processes, formulation know-how, analytical methods, supplier qualification, and quality systems rather than in enforceable, high-value patent claims.
Potential technical barriers include:
- Maintaining hemin stability during lyophilization.
- Controlling oxidation and degradation.
- Achieving consistent reconstitution.
- Controlling visible and subvisible particulate matter.
- Demonstrating compatibility with infusion materials.
- Establishing validated manufacturing specifications for a rare-disease product.
These factors can delay competition even when the legal patent position is weak. They do not, however, provide the same exclusionary certainty as an active composition or formulation patent.
What method-of-use patents cover hemin and porphyria treatment?
The principal use of hemin for injection is treatment of acute attacks of acute intermittent porphyria and related acute hepatic porphyrias. Any historical method-of-use protection would be expired or commercially immaterial given the product’s early approval date.
The larger method-of-treatment issue concerns newer therapies that reduce hepatic porphyrin synthesis or attack frequency. Givosiran, marketed as Givlaari by Alnylam, targets aminolevulinic acid synthase 1 and is approved for acute hepatic porphyria. It does not directly replace hemin, but it can reduce the recurrent attack burden that generates hemin demand. [4]
This creates a two-part market:
| Segment |
Role of hemin |
| Acute attack treatment |
Established rescue or attack-directed therapy |
| Long-term attack prevention |
Increasingly exposed to disease-modifying alternatives |
| Severe or refractory episodes |
Hemin remains clinically relevant |
| Patients without access to newer therapy |
Hemin remains a practical standard |
| Patients controlled on preventive therapy |
Lower potential hemin utilization |
How does hemin compare with Givlaari?
Hemin and Givlaari occupy different treatment positions. Hemin is an established intravenous product used around acute attacks. Givlaari is a subcutaneous RNA-interference therapy intended to reduce attack frequency and disease burden over time. [2,4]
| Factor |
Hemin for injection |
Givlaari |
| Treatment role |
Acute attack management |
Preventive disease modification |
| Route |
Intravenous |
Subcutaneous |
| Use pattern |
Episodic or attack-related |
Chronic scheduled dosing |
| Market impact |
Benefits from recurrent attacks |
Can reduce recurrent hemin demand |
| Commercial model |
Small, episodic specialty market |
Higher-value chronic orphan therapy |
| Competitive threat |
Limited direct substitution in emergencies |
Indirect threat through attack reduction |
| Patient selection |
Acute attacks and selected recurrent cases |
Patients with recurrent acute hepatic porphyria |
Givlaari is the most important long-term competitive factor for hemin. The impact is unlikely to eliminate hemin demand because preventive therapy does not remove the need for rescue treatment in every patient. Its effect is more likely to reduce treatment frequency among patients with recurrent attacks.
What patent litigation and settlement risks affect hemin?
The direct patent-litigation risk for Panhematin appears low because the product lacks a material current patent estate. The more relevant litigation risk exists around competing porphyria therapies, particularly patents covering RNA-interference constructs, delivery systems, dosing regimens, and methods for reducing porphyria attacks.
For hemin itself:
- No major active patent dispute is central to the market.
- No major Paragraph IV settlement is a known driver of market timing.
- Generic entry risk is operational and economic rather than primarily legal.
- A future entrant could seek approval without negotiating a conventional patent settlement if no blocking patent is listed.
Which companies are challenging the hemin market?
The competitive landscape is limited. The principal competitive pressure comes from:
- Generic injectable manufacturers assessing the commercial feasibility of hemin.
- Heme arginate suppliers outside the United States.
- Alnylam through Givlaari’s preventive treatment model.
- Specialist centers and hospitals using supportive measures such as glucose in selected clinical settings.
- Potential future therapies that reduce hepatic heme precursor production.
Heme arginate is clinically related but is not interchangeable with U.S.-approved Panhematin for regulatory and commercial purposes. Market comparisons must separate products by jurisdiction, indication, formulation, and approval status.
What generic launch scenarios exist for hemin injection?
Three scenarios are commercially plausible.
No generic entrant
Recordati retains the U.S. market because the patient base is too small and sterile manufacturing costs are too high. This supports continued pricing power and stable specialty revenue.
Single generic entrant
A single approved generic competes selectively on price and hospital contracts. Recordati may retain much of the market through brand familiarity, supply reliability, and specialist relationships. Price erosion could be meaningful but less severe than in high-volume oral generics.
Multiple generic entrants
Several suppliers compete after the first launch. This could produce sharper price declines, formulary substitution, and reduced brand share. The probability is lower than for standard high-volume products because the addressable market is small.
The most likely impact of a first generic would be a reduction in price and procurement leverage for hospitals rather than an immediate collapse in demand for the branded product.
What geographic markets drive hemin revenue?
The United States is the most commercially important market for Panhematin because Recordati has marketed the product there under a dedicated rare-disease platform. International markets use varying products and treatment practices, including heme arginate in some jurisdictions.
Geographic differences affect revenue through:
- Product approval and naming.
- Reimbursement rules.
- Hospital procurement systems.
- Availability of specialist porphyria centers.
- Emergency stockholding practices.
- Access to preventive therapy.
- Local treatment guidelines.
A global hemin market estimate that combines Panhematin with heme arginate can overstate the addressable market for any one supplier.
How strong is the patent estate for hemin for injection?
The patent estate is weak as a standalone exclusion strategy. Commercial strength comes from market structure rather than patent term.
| Asset characteristic |
Assessment |
| Composition-of-matter protection |
None of current commercial significance |
| Orphan exclusivity |
Expired |
| Formulation patents |
No material active barrier identified |
| Method-of-use patents |
Historical or commercially expired |
| Manufacturing know-how |
Potentially meaningful |
| Regulatory history |
Meaningful competitive advantage |
| Brand recognition |
Meaningful in specialist care |
| Supply reliability |
Potentially decisive |
| Generic entry defense |
Moderate operational defense, weak legal defense |
For investors or licensing teams, Panhematin should be valued as a durable niche product with execution-based protection. It should not be valued as a patent-protected growth asset.
What revenue exposure does Recordati have to hemin?
Recordati’s Panhematin revenue exposure is likely modest relative to consolidated company sales. The company does not separately report Panhematin sales, gross margin, prescription volume, or geographic revenue in its public annual reporting. [1]
The product can still have an attractive margin profile because:
- Manufacturing volumes are limited.
- Specialty distribution supports high unit economics.
- The product addresses a serious orphan condition.
- Physician and hospital switching costs are higher during acute treatment.
- Commercial infrastructure can be shared with other rare-disease products.
The principal downside is concentration. A manufacturing interruption, regulatory action, competitor launch, or successful preventive therapy could affect a small portfolio product disproportionately even if the impact on Recordati’s total revenue remains limited.
Key Takeaways
- Hemin for injection is a small, high-value orphan acute-care market led in the United States by Recordati’s Panhematin.
- Recordati does not disclose standalone Panhematin revenue, so a verified product-level financial trajectory is unavailable from public filings.
- Original orphan and regulatory exclusivity expired decades ago.
- The product has no apparent current patent estate capable of blocking generic development.
- Generic entry risk is constrained by sterile injectable manufacturing, limited market size, and specialist adoption requirements.
- Givlaari is the most important competitive threat because preventive treatment can reduce recurrent hemin use.
- Hemin remains difficult to replace during acute porphyria attacks.
- The product’s commercial protection comes from supply reliability, regulatory history, specialist relationships, and market concentration.
- Panhematin is best viewed as a mature, niche cash-generating asset rather than a patent-protected growth product.
FAQs About Hemin for Injection Market and Commercial Outlook
Is Panhematin a biologic drug?
No. Panhematin is an injectable hemin product and is not a monoclonal antibody or other conventional biologic. Its manufacturing and quality requirements are complex, but its regulatory and competitive analysis differs from that of biosimilars.
Is there a generic version of Panhematin?
A generic competitor would need FDA approval and compliant sterile manufacturing. The absence of a major patent barrier does not establish that a commercial generic is available or widely marketed.
Can Givlaari replace hemin?
No. Givlaari is a preventive therapy, while hemin is used primarily for acute attack management. Givlaari may reduce the frequency of hemin treatment without eliminating the need for rescue therapy.
Why is hemin expensive despite having no active patent monopoly?
Pricing reflects orphan-market economics, small manufacturing scale, specialized sterile production, emergency hospital demand, limited supplier competition, and the clinical cost of untreated attacks.
What is the main investment risk for hemin injection?
The main risks are a generic injectable entrant, manufacturing or supply disruption, expanded use of preventive porphyria therapy, and continued difficulty diagnosing patients who could generate treatment demand.
References
- Recordati S.p.A. (2024). Annual report 2023. Recordati S.p.A.
- U.S. Food and Drug Administration. (2023). Panhematin (hemin for injection) prescribing information. Recordati Rare Diseases Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (2019). Givlaari (givosiran) prescribing information. Alnylam Pharmaceuticals, Inc.
